Immuneering Corporation has released a corporate presentation focusing on their efforts to help cancer patients outlive their disease. The company is prioritizing durability and tolerability in their approach, aiming for longer patient survival with minimized adverse events. Their initial focus is on a Phase 2a trial for atebimetinib (IMM-1-104) combined with modified Gemcitabine and nab-Paclitaxel (mGnP) for first-line pancreatic cancer. The presentation highlights an impressive 94% 6-month overall survival rate for patients treated with this combination, based on interim data from an ongoing trial. The median overall survival has not been reached, indicating promising potential outcomes. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.